Arcutis Biotherapeutics Inc

10 de nov. de 2026, 21:06 UTC

Arcutis Biotherapeutics, Inc. shares are higher today, showing a strong early surge.

6 de nov. de 2026, 21:02 UTC

Arcutis Biotherapeutics grants 58.5k restricted stock units and options for 17k shares to new employees, while enrolling the first participant in a Phase 3 study.

5 de nov. de 2026, 23:26 UTC

Arcutis Biotherapeutics enrolls the first participant in its Phase 3 study, INTEGUMENT-3, amid significant declines in after-market trading.

4 de nov. de 2026, 23:02 UTC

Arcutis Biotherapeutics reports Q3 net income of $8.8M and revenue of $143.9M, but EPS of $0.06 misses expectations, leading to negative market sentiment.

3 de nov. de 2026, 23:21 UTC

Arcutis Biotherapeutics, Inc. shares are trading modestly lower in after-market hours, following a strong one-month performance above its 20-day moving average.

2 de nov. de 2026, 21:09 UTC

Arcutis Biotherapeutics shares are declining amid broader weakness in the biotechnology sector, influenced by significant drops in key holdings within the SPDR S&P Biotech ETF.

30 de out. de 2026, 19:36 UTC

Arcutis Biotherapeutics, Inc. is seeing modest gains, recovering from an earlier pullback and trading above its 20-day moving average.

29 de out. de 2026, 21:21 UTC

Arcutis Biotherapeutics, Inc. is trading modestly higher in after-market hours, reflecting strength in the Biotechnology sub-sector and continuing a strong performance trend.

27 de out. de 2026, 19:26 UTC

Arcutis Biotherapeutics, Inc. shares fell slightly, retracing some gains but remaining above its 20-day moving average and near the upper end of its one-month range.

26 de out. de 2026, 20:13 UTC

Arcutis Biotherapeutics Inc shares are trading lower in after-market hours, continuing a downward trend that began since Monday's close.

23 de out. de 2026, 20:01 UTC

Arcutis Biotherapeutics Inc shares are declining sharply, with a cumulative return significantly lower since Thursday's close, reflecting weaker performance compared to recent trends.

22 de out. de 2026, 20:07 UTC

Arcutis Biotherapeutics Inc shares are modestly higher, approaching their 52-week high, amid strong sales of ZORYVE and anticipation for Q3 earnings.

21 de out. de 2026, 19:36 UTC

Arcutis Biotherapeutics Inc shares fell sharply, retracing from earlier gains.

20 de out. de 2026, 22:26 UTC

Arcutis Biotherapeutics Inc shares are trading modestly lower in after-market hours, having retraced from a brief peak earlier in the session.

19 de out. de 2026, 22:01 UTC

Arcutis Biotherapeutics Inc is trading higher in after-market hours, following a strong position after Monday's close, despite a decline in the NAHB Housing Market Index.

16 de out. de 2026, 20:13 UTC

Arcutis Biotherapeutics Inc shares declined during after-market hours, aligning with broader market trends amid mixed economic data on inflation and fiscal management.

15 de out. de 2026, 20:01 UTC

Cantor Fitzgerald initiated coverage on Arcutis Biotherapeutics with an Overweight rating and a price target of $48, contributing to notable trading volume.

14 de out. de 2026, 22:52 UTC

Arcutis Biotherapeutics Inc shares are moving modestly lower in after-market hours, reflecting a broader market decline following a consumer inflation report.

13 de out. de 2026, 20:07 UTC

Arcutis Biotherapeutics Inc shares fell modestly, reaching a low in the morning before recovering but ultimately settling near the lower end of its range.

12 de out. de 2026, 20:06 UTC

Arcutis Biotherapeutics presented data on its ZORYVE® portfolio at two dermatology conferences, leading to a decline in shares during Monday's session.

9 de out. de 2026, 20:01 UTC

Arcutis Biotherapeutics presents positive ZORYVE data at EADV Congress, showing 34.4% of infants and 66.4% of patients achieving clear skin in trials.

8 de out. de 2026, 20:03 UTC

Arcutis Biotherapeutics Inc shares are gaining.

6 de out. de 2026, 20:00 UTC

Shares of Arcutis Biotherapeutics Inc fell despite the company's ZORYVE® cream winning the 2026 "Best Prescription Skin Solution" Award from Marie Claire magazine.

1 de out. de 2026, 20:07 UTC

Arcutis Biotherapeutics Inc shares fell sharply, continuing a trend of three consecutive lower daily closes amid challenges in the biotechnology sector.

29 de set. de 2026, 20:07 UTC

Arcutis Biotherapeutics launched the "Skin to Believe In" campaign with Simone Biles, as shares fell lower after an initial gain at market open.

28 de set. de 2026, 19:15 UTC

Arcutis Biotherapeutics Inc is trading higher, reaching a peak return of nearly 2% and remaining significantly above its 20-day moving average.

25 de set. de 2026, 20:07 UTC

Arcutis Biotherapeutics Inc is advancing during the session, building on gains since Thursday, trading above its 20-day moving average and near its one-month high.

24 de set. de 2026, 20:07 UTC

Arcutis Biotherapeutics Inc's shares fell, continuing a downward trend since Wednesday, despite earlier fluctuations that saw a pullback from a session high.

23 de set. de 2026, 20:01 UTC

Arcutis Biotherapeutics Inc shares fell sharply, breaking a recent trend of higher daily closes, diverging from the upward movement observed in prior sessions.

22 de set. de 2026, 20:01 UTC

Arcutis Biotherapeutics Inc is advancing sharply, continuing its upward trend since Monday's close, despite an earlier pullback from a session high.